1 Research Centre for Developmental Medicine and Biology, Department of Paediatrics, Auckland School of Medicine; University of Auckland, Auckland, New Zealand
2 Department of Paediatrics, National Womens Hospital, University of Auckland, Auckland, New Zealand
3 University Children's Hospital, Giessen, Germany
Address correspondence to: Tania R. Gunn, MBChB, MD, Research Centre for Developmental Medicine and Biology, Department of Paediatrics, University of Auckland, Private Bag, Auckland, New Zealand
Aims. To determine the galactopoietic response to recombinant human growth hormone (hGH) in mothers of premature infants with inadequate lactation.
Study Design. Prospective placebo-controlled, double-blind trial.
Subjects. Twenty healthy mothers on no concurrent medication, with infants born between 26 and 34 weeks' gestation with insufficient milk production for their infants' needs.
Interoentions. Ten mothers received hGH, .2 IU/kg/day subcutaneously to a maximum of 16 IU/day, for 7 days, while 10 mothers received the same volume of placebo. One mother from each group withdrew from the study.
Outcome Measures. Maternal milk production and plasma concentrations of insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and growth hormone (GH) were determined before starting treatment and 1 day after stopping therapy. A nurse measured the amount of milk expressed (5 to 6 times daily) plus, if the infant was suckling, weighed the infant before and after feeding.
Results. The mothers were enrolled 35 ± 26 days after birth; at this time the infants weighed 1.89 ± .64 kg. Milk production in hGH-treated mothers increased from 139 ± 49 mL/day to 175 ± 46 mL/day after 7 days of treatment (arise of 31%). Placebo-treated mothers showed no significant change from 93 ± 50 mL/day to 102 ± 69 mL/day (arise of 7.6%, not significant). Milk production increased in all treated mothers but decreased in 4 of 9 placebo mothers. Plasma concentrations of IGF-1 and IGFBP-3 increased in hGH-treated mothers but not placebo-treated mothers; there was no change in plasma GH levels in either group. No adverse effects were seen with hGH treatment in the mothers or infants.
Conclusions. hGH therapy in mothers with lactational insufficiency can improve breast milk volumes.
Submitted on June 19, 1995
This article has been cited by other articles:
![]() |
L. A. Jacobs, J. E. Dickinson, P. D. Hart, D. A. Doherty, and S. J. Faulkner Normal Nipple Position in Term Infants Measured on Breastfeeding Ultrasound J Hum Lact, February 1, 2007; 23(1): 52 - 59. [Abstract] [PDF] |
||||
![]() |
T. Slusher, R. Hampton, F. Bode-Thomas, S. Pam, F. Akor, and P. Meier Promoting the Exclusive Feeding of Own Mother's Milk through the Use of Hindmilk and Increased Maternal Milk Volume for Hospitalized, Low Birth Weight Infants (< 1800 grams) in Nigeria: A Feasibility Study J Hum Lact, May 1, 2003; 19(2): 191 - 198. [Abstract] [PDF] |
||||
![]() |
R. J Playford, C. E Macdonald, and W. S Johnson Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders Am. J. Clinical Nutrition, July 1, 2000; 72(1): 5 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. ETHERTON and D. E. BAUMAN Biology of Somatotropin in Growth and Lactation of Domestic Animals Physiol Rev, July 1, 1998; 78(3): 745 - 761. [Abstract] [Full Text] [PDF] |
||||